HMG-I/Y in human breast cancer cell lines

Breast Cancer Research and Treatment

Volumn 71, Issue 3, 2002, Pages 181-191

  Dolde, Christine E ^a   Mukherjee, Mita ^a   Cho, Chung ^a   Resar, Linda M S ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Hematology   (United States)

^c Departments of Pediatrics   (United States)

Author keywords

Antisense; Breast cancer; HMG I Y; Oncogene; Transformation

Indexed keywords

BINDING PROTEIN; DNA; ISOPROTEIN; ONCOPROTEIN; PROTEIN HMG I; PROTEIN HMG Y; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BURKITT LYMPHOMA; CANCER CELL CULTURE; CELL TRANSFORMATION; CHROMATIN; CONTROLLED STUDY; GENE EXPRESSION; GENE HMG 1; GENETIC CODE; HUMAN; HUMAN CELL; NUCLEIC ACID PROBE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL;

BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA1A PROTEIN; HUMANS; TUMOR CELLS, CULTURED;

EID: 0036202224     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014444114804     Document Type: Article

References (76)

1. Structural features of the HMG chromosomal proteins and their genes
2. High-mobility-group chromosomal proteins: Architectural components that facilitate chromatin function
3. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins
4. Chromosomal localization of the murine gene and 2 related sequences encoding high-mobility group I and Y proteins
5. Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y)
6. Organization, inducible expression and chromosomal localization of the human HMG-I(Y) nonhistone protein gene
7. High-mobility-group proteins and cancer - An emerging link
8. On the presence of two new high mobility group-like proteins in HeLa S3 cells
9. Multivalent DNA-binding properties of the HMG-I proteins
10. The A-T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure
11. A mammalian high mobility group protein recognizes any stretch of six A T base pairs in duplex DNA
12. Short peptide derived from HMG-I/Y proteins bind specifically to the minor groove of DNA
13. The high mobility group protein HMGI(Y) is required for NF-kappaB-dependent virus induction of the human IFN-β gene
14. The high mobility group protein HMG I(Y) is an essential structural component of viral-inducible enhancer complex
15. Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements
16. Virus induction of human IFN-β gene expression requires the assembly of an enhanceosome
17. Reversal of intrinsic DNA bends in the IFNβ gene enhancer by transcription factors and the architectural protein HMG I(Y)
18. SAR-dependent mobilization of histone H1 by HMG-I/Y in vitro: HMG-I/Y is enriched in H1-depleted chromatin
19. SARs are cis DNA elements of chromosome dynamics: Synthesis of a SAR repressor protein
20. In vivo analysis of scaffold-associated regions in Drosophila: A synthetic high-affinity SAR binding protein suppresses position effect variegation
21. Striking similarity in the organization of the E-selectin and beta interferon gene promoters
22. Cooperativity between two NF κB complexes, mediated by high-mobility-group protein I(Y), is essential for cytokine-induced expression of the E-selectin promoter
23. Induction of high mobility group-I(Y) protien by endotoxin and interleukin-1B in vascular smooth muscle cells: Role in activation of inducible nitric oxide synthetase
24. A poly(dA-dT) upstream activation sequence binds high-mobility group I protein and contributes to lymphotoxin (tumor necrosis factor-β) gene regulation
25. Regulation of cell-type-specific interleukin-2 receptor α-chain gene expression: Potential role of physical interactions between Elf-1, HMG-I(Y), and NF-κB family proteins
26. Binding of HMG-I(Y) imparts architectural specificity to a positioned nucleosome on the promoter of the human interleukin-2 receptor α gene
27. Multiple closely-linked NFAT/octamer and HMG I(Y) binding sites are part of the interleukin- 4 promoter
28. Sequence-specific binding of HMG-I(Y) to the proximal promoter of the gp91-phox gene
29. Sequence-specific binding of HMG-I(Y) to the proximal promoter of the gp91-phox gene (published erratum)
30. The non-histone chromosomal protein HMG-I(Y) contributes to repression of the immunoglobulin heavy chain germ-line epsilon RNA promoter
31. An HMG I(Y)-containing repressor complex and supercoiled DNA topology are critical for long-range enhancer-dependent transcription in vitro
32. Enhancement of serum-response factor-dependent transcription and DNA binding by the architectural factor HMG I(Y)
33. Changes in nuclear proteins on transformation of rat epithelial thyroid cells by a murine sarcoma retrovirus
34. Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v-ras and v-mos oncogenes and by co-transfection with c-myc and polyoma middle T genes
35. The expression of the high mobility group HMGI(Y) protein correlates with the malignant phenotype of human thyroid neoplasias
36. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells
37. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential indicator of carcinoma
38. Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures
39. Analysis of multiple forms of the HMGI proteins in rodent and human cells: Identification of the third protein, HMGI-C in human cells
40. Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix
41. Identification of high mobility group I(Y) as potential progression marker for prostate cancer by differential hybridization analysis
42. Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization
43. A retrospective study of high mobility group I(Y) as progressive marker for prostate cancer determined by in situ hybridization
44. HMG-I/Y: A new c-Myc target gene and potential oncogene
45. Elevated high mobility group I(Y) gene expression is associated with progressive transformation of mouse mammary epithelial cells
46. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer
47. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells
48. Function of the c-Myc oncogenic transcription factor
49. The oncogenic properties of the HMG-1 gene family
50. Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not-resistent cells
51. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias
52. Effects of epidermal growth factor and estrogen on the regulation of the HMG-I/Y gene in mammary epithelial cell lines
53. Two syngeneic cell lines from human breast tissue: The aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs587T) cell lines
54. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells
55. Inhibition of fibrillin 1 expression using U1 snRNA as a vehicle for the presentation of antisense targeting sequence
56. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors
57. Modulation of breast cancer progression and differentiation by the gp30/heregulin
58. MCF-7: The first hormone-responsive breast cancer cell line
59. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype
60. Transgenic mouse models of breast cancer
61. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours
62. Disruption of the architectural factor HMG-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains
63. From chromosomal aberrations to the high mobility group protein gene family: Evidence for a common denominator in benign solid tumor development
64. A fibroadenoma with a t(4;12)(q27;q15) affecting the HMGI-C gene, a member of the high mobility group protein family
65. HMGI-C rearrangements as the molecular basis for the majority of pulmonary chondroid hamartomas: A survey of 30 tumors
66. Translocations in solid tumors
67. Rearrangements of the high mobility group protein family genes and the molecular genetic origin of the uterine leiomyomas and endometrial polyps
68. Transcriptional activation of HMGI-C in three pulmonary hamartomas each with a del(14)t(12;14) as the sole cytogenetic abnormality
69. An endometrial poly with a rearrangement of HMGI-C underlying a complex cytogenetic rearrangement involving chromosomes 2 and 12
70. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors
71. Fusion transcripts between the HMGIC gene and RTVL-H-related sequences in mesenchymal tumors without cytogenetic aberrations
72. Expression of the reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland
73. HMGIC expressed in a uterine leiomyoma with a deletion of the long arm of chromosome 7 along with a 12q14-15 rearrangement but not in tumors showing del(7) as the sole cytogenetic abnormality
74. Chromosomal translocations in benign tumors. The HMGI proteins